Many different cell types produce HS chains with many different primary structures. Therefore, there is a great deal of variability in the way HS chains are synthesised, producing structural diversity encompassed by the term "heparanome" - which defines the full range of primary structures produced by a particular cell, tissue or organism. However, essential to the formation of HS regardless of primary sequence is a range of biosynthetic enzymes. These enzymes consist of multiple
glycosyltransferases,
sulfotransferases and an
epimerase. These same enzymes also synthesize
heparin. In the 1980s,
Jeffrey Esko was the first to isolate and characterize animal cell mutants altered in the assembly of heparan sulfate. Many of these
enzymes have now been purified, molecularly cloned and their expression patterns studied. From this and early work on the fundamental stages of HS/heparin biosynthesis using a mouse mastocytoma cell free system a lot is known about the order of enzyme reactions and specificity. Patients with
Multiple Hereditary Exostoses lack the ability to biosynthesize HS.
Chain initiation HS synthesis initiates with the transfer of
xylose from
UDP-xylose by
xylosyltransferase (XT) to specific
serine residues within the protein core. Attachment of two
galactose (Gal) residues by galactosyltransferases I and II (GalTI and GalTII) and
glucuronic acid (GlcA) by
glucuronosyltransferase I (GlcATI) completes the formation of a
tetrasaccharide primer O-linked to a serine of the core-protein: βGlcUA-(1→3)-βGal-(1→3)-βGal-(1→4)-βXyl-
O-Ser. The pathways for HS/heparin or
chondroitin sulfate (CS) and
dermatan sulfate (DS) biosynthesis diverge after the formation of this common tetrasaccharide linkage structure. The next enzyme to act, GlcNAcT-I or GalNAcT-I, directs synthesis, either to HS/heparin or CS/DS, respectively.
Xylose attachment to the core protein is thought to occur in the
endoplasmic reticulum (ER) with further assembly of the linkage region and the remainder of the chain occurring in the
Golgi apparatus. Mutations at the EXT1-3 gene loci in humans lead to an inability of cells to produce HS and to the development of the disease
Multiple Hereditary Exostoses (MHE). MHE is characterized by cartilage-capped tumours, known as osteochondromas or exostoses, which develop primarily on the long bones of affected individuals from early childhood until puberty.
Chain modification As an HS chain polymerises, it undergoes a series of modification reactions carried out by four classes of sulfotransferases and an epimerase. The availability of the sulfate donor
PAPS is crucial to the activity of the sulfotransferases.
N-deacetylation/N-sulfation The first polymer modification is the N-deacetylation/N-sulfation of GlcNAc residues into GlcNS. This is a prerequisite for all subsequent modification reactions, and is carried out by one or more members of a family of four GlcNAc N-deacetylase/N-sulfotransferase enzymes (NDSTs). In early studies, it was shown that modifying enzymes could recognize and act on any N-acetylated residue in the forming polymer. Therefore, the modification of GlcNAc residues should occur randomly throughout the chain. However, in HS, N-sulfated residues are mainly grouped together and separated by regions of N-acetylation where GlcNAc remains unmodified. There are four isoforms of NDST (NDST1–4). Both N-deacetylase and N-sulfotransferase activities are present in all NDST-isoforms but they differ significantly in their enzymatic activities.
Generation of GlcNH2 Due to the N-deacetylase and N-sulfotransferase being carried out by the same enzyme N-sulfation is normally tightly coupled to N-acetylation. GlcNH2 residues resulting from apparent uncoupling of the two activities have been found in heparin and some species of HS.
Epimerisation and 2-O-sulfation Epimerisation is catalysed by one enzyme, the GlcA C5 epimerase or heparosan-N-sulfate-glucuronate 5-epimerase (). This enzyme epimerases GlcA to
iduronic acid (IdoA). Substrate recognition requires that the GlcN residue linked to the non-reducing side of a potential GlcA target be N-sulfated. Uronosyl-2-O-sulfotransferase (2OST) sulfates the resulting IdoA residues.
6-O-sulfation Three glucosaminyl 6-O-transferases (6OSTs) have been identified that result in the formation of GlcNS(6S) adjacent to sulfated or non-sulfated IdoA. GlcNAc(6S) is also found in mature HS chains.
3-O-sulfation Currently seven
glucosaminyl 3-O-sulfotransferases (3OSTs, HS3STs) are known to exist in mammals (eight in zebrafish). The 3OST enzymes create a number of possible 3-
O-sulfated disaccharides, including GlcA-GlcNS(3S±6S) (modified by
HS3ST1 and
HS3ST5), IdoA(2S)-GlcNH2(3S±6S)(modified by
HS3ST3A1,
HS3ST3B1,
HS3ST5 and
HS3ST6) and GlcA/IdoA(2S)-GlcNS(3S) (modified by
HS3ST2 and
HS3ST4). As with all other HS sulfotransferases, the 3OSTs use
3'-phosphoadenosine-5'-phosphosulfate (PAPS) as a sulfate donor. Despite being the largest family of HS modification enzymes, the 3OSTs produce the rarest HS modification, the 3-
O-sulfation of specific glucosamine residues at the C3-OH moiety. The 3OSTs are divided into two functional subcategories, those that generate an
antithrombin III binding site (
HS3ST1 and
HS3ST5) and those that generate a
herpes simplex virus 1 glycoprotein D (HSV-1 gD) binding site (
HS3ST2,
HS3ST3A1,
HS3ST3B1,
HS3ST4,
HS3ST5 and
HS3ST6). As the 3OSTs are the largest family of HS modification enzymes and their actions are rate-limiting, substrate specific and produce rare modifications, it has been hypothesized that 3OST modified HS plays an important regulatory role in biological processes. ==Ligand binding==